Managing tuberculosis and HIV in sub-Sahara Africa
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abdool Karim SS, Abdool Karim Q, Friedland G, et al.: Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 2004, 18:975–980.
Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001, 15:143–152.
Connolly C, Reid A, Davies G, et al.: Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999, 13:1543–1547.
Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001, 15:143–152.
World Health Organization: Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2008.
Gandhi NR, Moll A, Sturm AW, et al.: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575–1580.
Nunn P, Zignol M, Jaramillo E, et al.: TB drug resistance: is it really a threat to Africa? Ethiop Med J 2007, 45:397–404.
Tsiouris SJ, Gandhi NR, El-Sadr WM, Friedland GF: Tuberculosis and HIV-needed: a new paradigm for the control and management of linked epidemics. Med Gen Med 2007, 9:62.
Joint United Nations Programme on HIV/AIDS: Report on the Global HIV/AIDS Epidemic, 2007. Geneva: World Health Organization; 2007.
Dlodlo RA, Fujiwara PI, Enarson DA: Should tuberculosis treatment and control be addressed differently in HIV-infected and-uninfected individuals? Eur Respir J 2005, 25:751–757.
World Health Organization: The Global MDR-TB and XRD-TB Response Plan 2007–2008. Geneva: World Health Organization; 2007.
Panel on Antiretroviral Guidelines for Adults and Adolescents: Mycobacterium tuberculosis disease or latent tuberculosis infection with HIV co-infection. In Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2008:52–54.
Shafer RW, Edlin BR: Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996, 22:683–704.
Lalloo UG, Ambaram A, Vawda F: Pulmonary complications. In International Atlas of AIDS. Edited by Mildvan D. Philadelphia: Current Medicine Group; 2007:135–150.
Pawinski RA, Lalloo UG: Multisectoral responses to HIV/AIDS: applying research to policy and practice. Am J Pub Health 2006, 96:1189–1191.
Pawinski RA, Pillay S, Abdool-Karim Q, et al.: Meeting the clinical training needs for the ARV roll-out in KwaZuluNatal. UKZN College Newsletter 2005, 1–4.
Chaisson RE, Martinson NA: Tuberculosis in Africa—combating an HIV-driven crisis. N Engl J Med 2008, 358:1089–1092.
Friedland G: Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr Infect Dis Rep 2007, 9:252–261.
Meya B, McAdam KPWJ: The TB pandemic: an old problem seeking new solutions. J Int Med 2007, 261:309–329.
The South African Tuberculosis Control Programme Practical Guidelines. Pretoria: Department of Health; 2000.
Tuberculosis Coalition for Technical Assistance: International Standards for Tuberculosis Care. The Hague: Tuberculosis Coalition for Technical Assistance; 2006.
Hopewell PC, Pai M, Maher D, et al.: International standards for tuberculosis care. Lancet Infect Dis 2006, 6:710–725.
Zignol M, Hosseini MS, Wright A, et al.: Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006, 194:479–485.
Grant AD, Charalambous S, Fielding KL, et al.: Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005, 293:2719–2725.
Hawken MP, Muhindi DW: Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Int J Tuberc Lung Dis 1999; 3:646–650.
Basu S, Andrews JR, Poolman EM, et al.: Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modeling study. Lancet 2007, 370:1500–1507.
Escombe AR, Oeser C, Gilman RH, et al.: The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis 2007, 44:1349–1357.
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603–662.
Korenromp EL, Scano F, Williams BG, et al.: Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin-based treatment: an analytic review. Clin Infect Dis 2003, 37:101–112.
Dheda K, Lampe FC, Johnson MA, Lipman MC: Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004, 190:1670–1676.
Dean GL, Edwards SG, Ives NJ, et al.: Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002, 16:75–83.
Zolopa A, Andersen J, Komarow I, et al.: Immediate vs deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A5164 [abstract 142]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008.
French MA: Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007, 4:16–21.
World Health Organization: Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2006.
Department of Health: National Antiretroviral Treatment Guidelines. Pretoria: National Department of Health South Africa; 2004.
Almond L, Gibbons S, Davies G, et al.: A retrospective survey of the Liverpool TDM service: factors influencing efavirenz concentrations in patients taking rifampicin. Presented at the 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada; April 28–30, 2005.
López-Cortés LF, Viciana P, Alarcon-Gonzalez A, et al.: Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002, 41:681–690.
Manosuthi W, Sungkanuparph S, Vibhagool A, Kiertiburanakul S: A randomized controlled trial of EFV 600 mg QD versus 800 mg QD in HIV-infected patients with tuberculosis to study EFV plasma levels, virologic and immunologic outcomes, a preliminary results [presentation OrB1013]. Presented at the XV International AIDS Conference. Bangkok, Thailand; July 11–16, 2004.
Lopez-Cortes LF, Ruiz R, Viciana P, et al.: Pharmacokinetic interactions between rifampin and efavirenz in patients with tuberculosis and HIV infection. Presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4–8, 2001.
Friedland G, Khoo S, Jack C, Lalloo UG: Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicr Chemo 2006, 58:1299–1302.
Jack C, Lalloo U, Abdool Karim Q, et al.: A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquire Immune Defic Syndr 2004, 36:929–934.
Gandhi N, Moll A, Pawinski R, et al.: Favorable outcomes of integration of TB and HIV treatment in rural South Africa: the Sizonqoba study. Presented at the XVI International AIDS Conference. Toronto, Canada; August 13–16, 2006.